BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gupta A, Marzook H, Ahmad F. Comorbidities and clinical complications associated with SARS-CoV-2 infection: an overview. Clin Exp Med 2022. [PMID: 35362771 DOI: 10.1007/s10238-022-00821-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Sara El-Sayed Abd El-Ghani, Reham Mohammad Raafat Hamed, Ragaey Ahmad Eid, Ahmed Yassin Mohammed Ibrahim, Hoda M. Abdel-Hamid, Walaa Abdelrahman, Raghda Ebaid Ibrahim, Manar Mahmoud Abdel-Aziz, Marwa Salah Mohamed. Serum interleukin 1β and sP-selectin as biomarkers of inflammation and thrombosis, could they be predictors of disease severity in COVID 19 Egyptian patients? (a cross-sectional study). Thromb J 2022;20:77. [PMID: 36522776 DOI: 10.1186/s12959-022-00428-5] [Reference Citation Analysis]
2 Hassen J, Getinet T, Botore A, Bekele M, Bekele B, Jalata F, Abebe W, Sisay M, Getahun A, Ligidi T. Mortality due to SARS COV-2 And its Associated Factors in East Shewa Zone Treatment Centers, Ethiopia, 2022: A retrospective cross-sectional study.. [DOI: 10.1101/2022.11.28.22282830] [Reference Citation Analysis]
3 Gül F, Gonen ZB, Jones OY, Taşlı NP, Zararsız G, Ünal E, Özdarendeli A, Şahin F, Eken A, Yılmaz S, Karakukçu M, Kırbaş OK, Gökdemir NS, Bozkurt BT, Özkul Y, Oktay BD, Uygut MA, Cinel I, Çetin M. A pilot study for treatment of severe COVID-19 pneumonia by aerosolized formulation of convalescent human immune plasma exosomes (ChipEXO™). Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.963309] [Reference Citation Analysis]
4 Gül F, Gonen ZB, Jones OY, Taşlı NP, Zararsız G, Ünal E, Özdarendeli A, Şahin F, Eken A, Yılmaz S, Karakukçu M, Kırbaş OK, Gökdemir NS, Bozkurt BT, Özkul Y, Oktay BD, Uygut MA, Cinel I, Çetin M. A pilot study for treatment of severe COVID-19 pneumonia by aerosolized formulation of convalescent human immune plasma exosomes (ChipEXO™). Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.963309] [Reference Citation Analysis]
5 Gül F, Gonen ZB, Jones OY, Taşlı NP, Zararsız G, Ünal E, Özdarendeli A, Şahin F, Eken A, Yılmaz S, Karakukçu M, Kırbaş OK, Gökdemir NS, Bozkurt BT, Özkul Y, Oktay BD, Uygut MA, Cinel I, Çetin M. A pilot study for treatment of severe COVID-19 pneumonia by aerosolized formulation of convalescent human immune plasma exosomes (ChipEXO™). Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.963309] [Reference Citation Analysis]
6 Mello VD, Pereira VDP, Rodrigues JPV, Penteado STDS, Pereira LRL, Varallo FR. Eventos adversos no sistema nervoso central potencialmente relacionados aos medicamentos utilizados na COVID-19: revisão de escopo. Revista Panamericana de Salud Pública 2022;46:1. [DOI: 10.26633/rpsp.2022.166] [Reference Citation Analysis]
7 Gupta A, Qaisar R, Halwani R, Kannan M, Ahmad F. TFPI and FXIII negatively and S100A8/A9 and Cystatin C positively correlate with D-dimer in COVID-19. Exp Biol Med (Maywood) 2022;247:1570-6. [PMID: 35723053 DOI: 10.1177/15353702221102117] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Gupta A, Jayakumar MN, Saleh MA, Kannan M, Halwani R, Qaisar R, Ahmad F. SARS-CoV-2 infection- induced growth factors play differential roles in COVID-19 pathogenesis. Life Sci 2022;304:120703. [PMID: 35700841 DOI: 10.1016/j.lfs.2022.120703] [Cited by in F6Publishing: 1] [Reference Citation Analysis]